Ataxia telangiectasia overview

Jump to navigation Jump to search


Ataxia telangiectasia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Ataxia telangiectasia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Diagnostic Studies

Treatment

Medical Therapy

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ataxia telangiectasia overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ataxia telangiectasia overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ataxia telangiectasia overview

CDC on Ataxia telangiectasia overview

Ataxia telangiectasia overview in the news

Blogs on Ataxia telangiectasia overview

Directions to Hospitals Treating Ataxia telangiectasia

Risk calculators and risk factors for Ataxia telangiectasia overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ataxia-telangiectasia (AT) is an autosomal recessive inheritance, characterized by progressive cerebellar ataxia with degeneration of Purkinje cells beginning in early childhood, usually before age 5. Patients with ataxia telangiectasia have increased cancer incidence especially for leukemia and lymphoma. Affective individuals also have hypersensitivity of fibroblasts and lymphocytes to ionizing radiation, non-random chromosomal rearrangements in lymphocytes, thymic hypoplasia with cellular and humoral (IgA and IgG2) immunodeficiencies, elevated serum level of alphafetoprotein AFP, premature aging, and endocrine disorders (e.g. diabetes mellitus DM).

References

Template:WH

Template:WS